3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
6
Glioblastoma
5
Esophageal Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Childhood Brain Neoplasm
2
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pancreatic carcinoma, familial
1
Pancreatic Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Neoplasms
1
Malignant Solid Neoplasm
1
Lung Carcinoma Metastatic in the Brain
1
Kidney Neoplasms
1
Ischemic Stroke
1
Hypoxia
1
Interventions
Ibandronic Acid
8
Gemcitabine
8
Doxorubicin
6
Cyclophosphamide
6
Zoledronic Acid
5
Radiation
4
Nivolumab
4
Irinotecan
4
pembrolizumab
3
Vincristine
3
Temozolomide
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Docetaxel
3
Cisplatin
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
regorafenib
2
pegfilgrastim
2
Tranexamic Acid
2
Trabectedin
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiosurgery
2
Proton Therapy
2
Methotrexate
2
Injections
2
Ifosfamide
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bone Neoplasms
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts